No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: A randomized crossover trial

Kidney International

Volumn 80, Issue 8, 2011, Pages 841-850

  Hansen, Ditte ^a   Rasmussen, Knud ^a   Danielsen, Henning ^b   Meyer Hofmann, Helmut ^c   Bacevicius, Egidijus ^c   Lauridsen, Thomas G ^d   Madsen, Jens K ^e   Tougaard, Birgitte G ^e   Marckmann, Peter ^f   Thye Roenn, Peter ^g   Nielsen, Jørgen E ^h   Kreiner, Svend ⁱ   Brandi, Lisbet ^a  

^a ROSKILDE HOSPITAL   (Denmark)

^b VIBORG HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d HOLSTEBRO HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g ESBJERG HOSPITAL   (Denmark)

^h HOLBÆK HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

activated vitamin D; hemodialysis; hyperparathyroidism; mineral metabolism

Indexed keywords

25 HYDROXYERGOCALCIFEROL; ALBUMIN; ALFACALCIDOL; CALCIFEDIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; HEMOGLOBIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEATH; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HEMODYNAMIC PARAMETERS; HERPES SIMPLEX ENCEPHALITIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SEPTICEMIA; SIDE EFFECT; SKIN MANIFESTATION;

EID: 80053562092     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.226     Document Type: Article

References (56)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119. (Pubitemid 28527268)
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483. (Pubitemid 30318271)
4. Adeney KL, Siscovick DS, Ix JH et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-387.
5. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
6. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
7. Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138. (Pubitemid 32880350)
8. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528. (Pubitemid 41725150)
9. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005; 46: 68-77. (Pubitemid 40848434)
10. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
11. Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002; 91: 103-111. (Pubitemid 34522839)
12. Wang M, Hercz G, Sherrard DJ et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26: 836-844.
13. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366. (Pubitemid 44435190)
14. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
15. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28. (Pubitemid 40863568)
16. Slatopolsky E, Finch J, Ritter C et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852-860.
17. Palmer SC, McGregor DO, Craig JC et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2009: CD005633.
18. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1, 25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-284. (Pubitemid 34577479)
19. Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxyvitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999; 10: 980-985. (Pubitemid 29203084)
20. Abdul Gafor AH, Saidin R, Loo CY; et al. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. Nephrology (Carlton ) 2009; 14: 488-492.
21. Coyne DW, Grieff M, Ahya SN et al. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxyvitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002; 40: 1283-1288. (Pubitemid 35403141)
22. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38: S45-S50. (Pubitemid 33022205)
23. Lund RJ, Andress DL, Amdahl M et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. Am J Nephrol 2010; 31: 165-170.
24. Martin KJ, Gonzalez EA, Gellens ME et al. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2. Am J Kidney Dis 1998; 32: S61-S66.
25. Mittman N, Desiraju B, Meyer KB et al. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int Suppl 2010: S33-S36.
26. Monier-Faugere MC, Mawad H, Malluche HH. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal- parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1255-1260.
27. Seeherunvong W, Nwobi O, Abitbol CL et al. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 2006; 21: 1434-1439. (Pubitemid 44283476)
28. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490. (Pubitemid 36350014)
29. Sprague SM, Lerma E, McCormmick D et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001; 38: S51-S56. (Pubitemid 33022206)
30. Vulpio C, Maresca G, Distasio E et al. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: responsiveness is related to parathyroid gland size. Hemodial Int 2011, doi:10.1111/j.1542-4758.2010.00514.x.
31. Saarem K, Pedersen JI. 25-Hydroxylation of 1 alpha-hydroxyvitamin D-3 in rat and human liver. Biochim Biophys Acta 1985; 840: 117-126. (Pubitemid 15042020)
32. Brandi L, Egfjord M, Olgaard K. Pharmacokinetics of 1,25(OH)(2)D(3) and 1alpha(OH)D(3) in normal and uraemic men. Nephrol Dial Transplant 2002; 17: 829-842. (Pubitemid 34521135)
33. Brown AJ, Ritter CS, Knutson JC et al. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrol Dial Transplant 2006; 21: 644-650. (Pubitemid 43372909)
34. el-Reshaid K, el-Reshaid W, Sugathan T., et al. Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 1997; 17: 505-510. (Pubitemid 27499850)
35. Kiattisunthorn K, Wutyam K, Indranoi A et al. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology (Carlton) 2011; 16: 277-284.
36. Moe S, Wazny LD, Martin JE. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Can J Clin Pharmacol 2008; 15: e36-e43. (Pubitemid 351162493)
37. Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276. (Pubitemid 43121329)
38. Akiba T, Marumo F, Owada A et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998; 32: 238-246.
39. Greenbaum LA, Benador N, Goldstein SL et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 2007; 49: 814-823. (Pubitemid 46802931)
40. Wesseling-Perry K, Pereira RC, Sahney S et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011; 79: 112-119.
41. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435. (Pubitemid 38787398)
42. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008. (Pubitemid 350224109)
43. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131. (Pubitemid 350056006)
44. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16: 200-257.
45. Takahashi F, Finch JL, Denda M et al. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30: 105-112. (Pubitemid 27284381)
46. Dusso A, Tokumoto A, Brown A et al. New vitamin D analogs for chronic kidney disease patients. In: Olgaard K, Salusky IB, Silver J (eds). The Spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. Oxford University Press, New York, 2010 pp 417-441.
47. Panda DK, Miao D, Bolivar I et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279: 16754-16766. (Pubitemid 38509378)
48. Martin KJ, Gonzalez E, Lindberg JS et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 2001; 38: S57-S63. (Pubitemid 33022207)
49. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. (Pubitemid 44215354)
50. Shinaberger CS, Kopple JD, Kovesdy CP et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1769-1776.
51. Brandi L, Daugaard H, Tvedegaard E et al. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 1992; 12: 311-318. (Pubitemid 23039904)
52. Bailie GR, Johnson CA. Comparative review of the pharmacokinetics of vitamin D analogues. Semin Dial 2002; 15: 352-357.
53. Brown AJ, Zhong M, Finch J et al. The roles of calcium and 1, 25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 1995; 136: 1419-1425.
54. Wiese RJ, Uhland-Smith A, Ross TK et al. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992; 267: 20082-20086.
55. Hansen D, Brandi L, Rasmussen K. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. BMC Nephrol 2009; 10: 28.
56. Altman, D.G. (eds.). Practical Statistics for Medical Research. Chapmann & Hall/CRC: Boca Raton, 1991.